Patent · US Active

Prevention and treatment of synucleinopathic and amyloidogenic disease

US8506959B2 · kind B2 · utility

9Cited by

40References

15Claims

0Family size

Assignees

Neotope Biosciences Limited · IE
The Regents of the University of California · US

Inventors

Dale B. Schenk · Burlingame, US
Eliezer Masliah · San Diego, US
Manuel J. Buttini · Emeryville, US
Tamie J. Chilcote · San Francisco, US
Edward Rockenstein · San Diego, US
Kate Dora Games · Belmont, US

Key dates

Filing date	Jul 19, 2005
Grant date	Aug 13, 2013
Priority date	—
Expiry date	Aug 30, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.